On February 22-23, Xstrahl took part in the workshop hosted by the Nuclear Threat Initiative (NTI) and Emory University for various institutions in Atlanta, Georgia on radiological security which included representatives from the Center for Disease Control (CDC), the...
Xstrahl is delighted to invite you to ESTRO 37 taking place in Barcelona on 20 – 23 April. Join us at Booth 5100 to explore innovative applications of X-ray technology, where we will be showcasing the latest achievements in the medicine and life science. Our medical...
Cancer is a complex disease, with a variety of approaches available for its treatment. Treatment modalities are often combined to maximize response and to overcome the limitations of individual modalities when used alone. One such example is the combination of...
Risk Capital Partners, the private equity firm chaired by Luke Johnson, today announces that it has bought a majority stake in Xstrahl, a medical devices business that designs and delivers effective clinical and research solutions to advance radiation oncology....
On January 29 - 30 the Nuclear Threat Initiative (NTI) together with the University of California and National Nuclear Security Administration (NNSA) held technical discussions on radiological risks associated with using cesium-137 irradiators for research and blood...
PURPOSE: The Small Animal Radiation Research Platform (SARRP) has been developed for conformal microirradiation with on-board cone beam CT (CBCT) guidance. The graphics processing unit (GPU)-accelerated Superposition-Convolution (SC) method for dose computation has...
Chemotherapy has been successfully used to reduce radiation dose and volume for most pediatric patients. However, because of the failure of chemotherapeutic agents to cross the blood-brain barrier and the lack of response of some brain tumors to these agents,...
Accidental high-dose radiation exposure can result in mortality or severe morbidity through acute radiation syndrome (ARS). The early risk of death from ARS can be attributed mainly to radiation-induced gastrointestinal syndrome (RIGS). Currently, there are no readily...
BACKGROUND: Esophageal cancer is an aggressive disease with poor survival rates. A more patient-tailored approach based on predictive biomarkers could improve outcome. We aimed to predict radiotherapy (RT) response by imaging tumor hypoxia with 18F-FAZA PET/CT in an...
Contact Us